ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma : a single institution result of 127 patients
From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT). Patients received fixed dose G-CSF 300 micr...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2006-02, Vol.37 (3), p.277-282 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 282 |
|---|---|
| container_issue | 3 |
| container_start_page | 277 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 37 |
| creator | AKHTAR, S TBAKHI, A HUMAIDAN, H EL WESHI, A RAHAL, M MAGHFOOR, I |
| description | From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT). Patients received fixed dose G-CSF 300 microg SC bid starting 24-36 h after finishing mobilizing ESHAP. In all, four patients failed mobilization and are excluded. Characteristics of 127 patients: 68 males: 59 females. DLCL 49: HD 78. Initial stage I:II:III:IV:unknown was 15:34:33:42:3. Median age at ASCT 26 years. Median prior chemotherapy cycles were six [8 (20 patients)]. Median ESHAP cycle used as mobilizer was third. Patients required 1, 2, 3, 4 apheresis were 93:25:8:1. Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001). We conclude that ESHAP and G-CSF 300 microg SC bid is an effective mobilizing regimen even in patients >70 kg and most patients require only 1-2 apheresis. |
| doi_str_mv | 10.1038/sj.bmt.1705239 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_70724011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A182345133</galeid><sourcerecordid>A182345133</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-3c1b5774c345402f76e3bacb551cbbb7fd023f7e70267b6f7d41ebc88b47a1cd3</originalsourceid><addsrcrecordid>eNp1ksFv0zAYxSMEYmNw5YgsEOOAWuzYsRNuVbWtSJNAGpwj27FTF8cOtiMofyh_Dy6LKKChHBI5v--9fC-vKJ4iuEQQ12_ibimGtEQMViVu7hWniDC6qDCt7hensKT1AmPanBSPYtxBiAiB1cPiBFECISbVafHj4maz-gBeA22-qQ50PipwtVjfXAIeAZ-St773UwSjCmbcqsAtENb7DsSkBiCVtWDwwljznSfjHQiqN4NywDgw5hPlUgRfTdrmF5aPMVv4kJ914DL5sAed0XrKnpaHXt3qcdeBje_6z8a9isDuh3HrBw7eAg6icb1VWTwmk6bZME42Aa8BKtlvz8fFA81tVE_m-1nx6fLi43qzuH5_9W69ul5I3KC0wBKJijEicxYElppRhQWXoqqQFEIw3cESa6ZYTpIJqllHkBKyrgVhHMkOnxXnt7pj8F8mFVM7mHjYgjuVY2sZZCWBCGXwxT_gzk_B5W9rS0pKVEPGaKae_5dClFawbJqjVM-tao3TPuU0D77tCtVlXgVhnKnlHVS-OjUY6Z3SJp__NXD-x8BWcZu20dtfKcc7lWXwMeZ_2Y7BDDzsWwTbQynbuGtzKdu5lHng2bzVJAbVHfG5hRl4OQM8Sm5zOZw08cgxSiEhDf4J_k3qsw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216650299</pqid></control><display><type>article</type><title>ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma : a single institution result of 127 patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><creator>AKHTAR, S ; TBAKHI, A ; HUMAIDAN, H ; EL WESHI, A ; RAHAL, M ; MAGHFOOR, I</creator><creatorcontrib>AKHTAR, S ; TBAKHI, A ; HUMAIDAN, H ; EL WESHI, A ; RAHAL, M ; MAGHFOOR, I</creatorcontrib><description>From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT). Patients received fixed dose G-CSF 300 microg SC bid starting 24-36 h after finishing mobilizing ESHAP. In all, four patients failed mobilization and are excluded. Characteristics of 127 patients: 68 males: 59 females. DLCL 49: HD 78. Initial stage I:II:III:IV:unknown was 15:34:33:42:3. Median age at ASCT 26 years. Median prior chemotherapy cycles were six [<6 (17 patients), 6-8 (90 patients), >8 (20 patients)]. Median ESHAP cycle used as mobilizer was third. Patients required 1, 2, 3, 4 apheresis were 93:25:8:1. Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001). We conclude that ESHAP and G-CSF 300 microg SC bid is an effective mobilizing regimen even in patients >70 kg and most patients require only 1-2 apheresis.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/sj.bmt.1705239</identifier><identifier>PMID: 16400345</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject><![CDATA[Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Apheresis ; Autografts ; Biological and medical sciences ; Blood ; Blood Component Removal - methods ; Bone marrow ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Cancer ; Care and treatment ; CD34 antigen ; Chemotherapy ; Cisplatin - administration & dosage ; Cytarabine - administration & dosage ; Diagnosis ; Etoposide - administration & dosage ; Female ; Granulocyte colony-stimulating factor ; Granulocyte Colony-Stimulating Factor - administration & dosage ; Health aspects ; Hematologic and hematopoietic diseases ; Hematopoietic Stem Cell Mobilization - methods ; Hematopoietic stem cells ; Hodgkin Disease - therapy ; Hodgkin's disease ; Hodgkin's lymphoma ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - therapy ; Male ; Medical sciences ; Methylprednisolone - administration & dosage ; Peripheral blood ; Peripheral Blood Stem Cell Transplantation - methods ; Recurrence ; Retrospective Studies ; Risk factors ; Stem cell transplantation ; Stem cells ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation ; Transplantation, Autologous]]></subject><ispartof>Bone marrow transplantation (Basingstoke), 2006-02, Vol.37 (3), p.277-282</ispartof><rights>2006 INIST-CNRS</rights><rights>COPYRIGHT 2006 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Feb 2006</rights><rights>Nature Publishing Group 2006.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-3c1b5774c345402f76e3bacb551cbbb7fd023f7e70267b6f7d41ebc88b47a1cd3</citedby><cites>FETCH-LOGICAL-c391t-3c1b5774c345402f76e3bacb551cbbb7fd023f7e70267b6f7d41ebc88b47a1cd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17660449$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16400345$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>AKHTAR, S</creatorcontrib><creatorcontrib>TBAKHI, A</creatorcontrib><creatorcontrib>HUMAIDAN, H</creatorcontrib><creatorcontrib>EL WESHI, A</creatorcontrib><creatorcontrib>RAHAL, M</creatorcontrib><creatorcontrib>MAGHFOOR, I</creatorcontrib><title>ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma : a single institution result of 127 patients</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><description>From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT). Patients received fixed dose G-CSF 300 microg SC bid starting 24-36 h after finishing mobilizing ESHAP. In all, four patients failed mobilization and are excluded. Characteristics of 127 patients: 68 males: 59 females. DLCL 49: HD 78. Initial stage I:II:III:IV:unknown was 15:34:33:42:3. Median age at ASCT 26 years. Median prior chemotherapy cycles were six [<6 (17 patients), 6-8 (90 patients), >8 (20 patients)]. Median ESHAP cycle used as mobilizer was third. Patients required 1, 2, 3, 4 apheresis were 93:25:8:1. Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001). We conclude that ESHAP and G-CSF 300 microg SC bid is an effective mobilizing regimen even in patients >70 kg and most patients require only 1-2 apheresis.</description><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Apheresis</subject><subject>Autografts</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Blood Component Removal - methods</subject><subject>Bone marrow</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>CD34 antigen</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Cytarabine - administration & dosage</subject><subject>Diagnosis</subject><subject>Etoposide - administration & dosage</subject><subject>Female</subject><subject>Granulocyte colony-stimulating factor</subject><subject>Granulocyte Colony-Stimulating Factor - administration & dosage</subject><subject>Health aspects</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematopoietic Stem Cell Mobilization - methods</subject><subject>Hematopoietic stem cells</subject><subject>Hodgkin Disease - therapy</subject><subject>Hodgkin's disease</subject><subject>Hodgkin's lymphoma</subject><subject>Humans</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methylprednisolone - administration & dosage</subject><subject>Peripheral blood</subject><subject>Peripheral Blood Stem Cell Transplantation - methods</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation</subject><subject>Transplantation, Autologous</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1ksFv0zAYxSMEYmNw5YgsEOOAWuzYsRNuVbWtSJNAGpwj27FTF8cOtiMofyh_Dy6LKKChHBI5v--9fC-vKJ4iuEQQ12_ibimGtEQMViVu7hWniDC6qDCt7hensKT1AmPanBSPYtxBiAiB1cPiBFECISbVafHj4maz-gBeA22-qQ50PipwtVjfXAIeAZ-St773UwSjCmbcqsAtENb7DsSkBiCVtWDwwljznSfjHQiqN4NywDgw5hPlUgRfTdrmF5aPMVv4kJ914DL5sAed0XrKnpaHXt3qcdeBje_6z8a9isDuh3HrBw7eAg6icb1VWTwmk6bZME42Aa8BKtlvz8fFA81tVE_m-1nx6fLi43qzuH5_9W69ul5I3KC0wBKJijEicxYElppRhQWXoqqQFEIw3cESa6ZYTpIJqllHkBKyrgVhHMkOnxXnt7pj8F8mFVM7mHjYgjuVY2sZZCWBCGXwxT_gzk_B5W9rS0pKVEPGaKae_5dClFawbJqjVM-tao3TPuU0D77tCtVlXgVhnKnlHVS-OjUY6Z3SJp__NXD-x8BWcZu20dtfKcc7lWXwMeZ_2Y7BDDzsWwTbQynbuGtzKdu5lHng2bzVJAbVHfG5hRl4OQM8Sm5zOZw08cgxSiEhDf4J_k3qsw</recordid><startdate>200602</startdate><enddate>200602</enddate><creator>AKHTAR, S</creator><creator>TBAKHI, A</creator><creator>HUMAIDAN, H</creator><creator>EL WESHI, A</creator><creator>RAHAL, M</creator><creator>MAGHFOOR, I</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>200602</creationdate><title>ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma : a single institution result of 127 patients</title><author>AKHTAR, S ; TBAKHI, A ; HUMAIDAN, H ; EL WESHI, A ; RAHAL, M ; MAGHFOOR, I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-3c1b5774c345402f76e3bacb551cbbb7fd023f7e70267b6f7d41ebc88b47a1cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Apheresis</topic><topic>Autografts</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Blood Component Removal - methods</topic><topic>Bone marrow</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>CD34 antigen</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Cytarabine - administration & dosage</topic><topic>Diagnosis</topic><topic>Etoposide - administration & dosage</topic><topic>Female</topic><topic>Granulocyte colony-stimulating factor</topic><topic>Granulocyte Colony-Stimulating Factor - administration & dosage</topic><topic>Health aspects</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematopoietic Stem Cell Mobilization - methods</topic><topic>Hematopoietic stem cells</topic><topic>Hodgkin Disease - therapy</topic><topic>Hodgkin's disease</topic><topic>Hodgkin's lymphoma</topic><topic>Humans</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methylprednisolone - administration & dosage</topic><topic>Peripheral blood</topic><topic>Peripheral Blood Stem Cell Transplantation - methods</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation</topic><topic>Transplantation, Autologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>AKHTAR, S</creatorcontrib><creatorcontrib>TBAKHI, A</creatorcontrib><creatorcontrib>HUMAIDAN, H</creatorcontrib><creatorcontrib>EL WESHI, A</creatorcontrib><creatorcontrib>RAHAL, M</creatorcontrib><creatorcontrib>MAGHFOOR, I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>AKHTAR, S</au><au>TBAKHI, A</au><au>HUMAIDAN, H</au><au>EL WESHI, A</au><au>RAHAL, M</au><au>MAGHFOOR, I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma : a single institution result of 127 patients</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><addtitle>Bone Marrow Transplant</addtitle><date>2006-02</date><risdate>2006</risdate><volume>37</volume><issue>3</issue><spage>277</spage><epage>282</epage><pages>277-282</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT). Patients received fixed dose G-CSF 300 microg SC bid starting 24-36 h after finishing mobilizing ESHAP. In all, four patients failed mobilization and are excluded. Characteristics of 127 patients: 68 males: 59 females. DLCL 49: HD 78. Initial stage I:II:III:IV:unknown was 15:34:33:42:3. Median age at ASCT 26 years. Median prior chemotherapy cycles were six [<6 (17 patients), 6-8 (90 patients), >8 (20 patients)]. Median ESHAP cycle used as mobilizer was third. Patients required 1, 2, 3, 4 apheresis were 93:25:8:1. Median total CD34+ cells/kg collected were 6.9 x 10(6) (DLCL 5.17 x 10(6) and HD 7.6 x 10(6)), patients weighing < or = 70 kg (93 patients) 6.54 x 10(6) and >70 kg (34 patients) 7.44 x 10(6) (P = 0.59), one apheresis (93 patients) 8.6 x 10(6)/kg and >1 apheresis (34 patients) 4.5 x 10(6) (P = 0.001). We conclude that ESHAP and G-CSF 300 microg SC bid is an effective mobilizing regimen even in patients >70 kg and most patients require only 1-2 apheresis.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>16400345</pmid><doi>10.1038/sj.bmt.1705239</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2006-02, Vol.37 (3), p.277-282 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70724011 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature - Complete Springer Journals; Nature Journals Online |
| subjects | Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antineoplastic Combined Chemotherapy Protocols - administration & dosage Apheresis Autografts Biological and medical sciences Blood Blood Component Removal - methods Bone marrow Bone marrow, stem cells transplantation. Graft versus host reaction Cancer Care and treatment CD34 antigen Chemotherapy Cisplatin - administration & dosage Cytarabine - administration & dosage Diagnosis Etoposide - administration & dosage Female Granulocyte colony-stimulating factor Granulocyte Colony-Stimulating Factor - administration & dosage Health aspects Hematologic and hematopoietic diseases Hematopoietic Stem Cell Mobilization - methods Hematopoietic stem cells Hodgkin Disease - therapy Hodgkin's disease Hodgkin's lymphoma Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma Lymphoma, Large B-Cell, Diffuse - therapy Male Medical sciences Methylprednisolone - administration & dosage Peripheral blood Peripheral Blood Stem Cell Transplantation - methods Recurrence Retrospective Studies Risk factors Stem cell transplantation Stem cells Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation, Autologous |
| title | ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma : a single institution result of 127 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T03%3A53%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ESHAP%20+%20fixed%20dose%20G-CSF%20as%20autologous%20peripheral%20blood%20stem%20cell%20mobilization%20regimen%20in%20patients%20with%20relapsed%20or%20refractory%20diffuse%20large%20cell%20and%20Hodgkin's%20lymphoma%20:%20a%20single%20institution%20result%20of%20127%20patients&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=AKHTAR,%20S&rft.date=2006-02&rft.volume=37&rft.issue=3&rft.spage=277&rft.epage=282&rft.pages=277-282&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/sj.bmt.1705239&rft_dat=%3Cgale_proqu%3EA182345133%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216650299&rft_id=info:pmid/16400345&rft_galeid=A182345133&rfr_iscdi=true |